Serum selenium concentration and disease progress in patients with HIV infection

Cirelli, A; Ciardi, Maria; Simone, Claudio De; Sorice, F; Giordano, Rosaria; Ciaralli, Laura; Costantini, Sergio

doi:10.1016/0009-9120(91)90601-a

Cited by 90 publications

(43 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study demonstrates that serum selenium concentration declines with disease progression in HIV-infected individuals; these results agree with the observations of previous investigators (Dworkin et al, 1988;Olmsted et al, 1989;Beck et al, 1990;Cirelli et al, 1991;Dworkin, 1994).…”

Section: Discussionsupporting

confidence: 93%

Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection

Look

Rockstroh

Rao³

et al. 1997

Eur J Clin Nutr

138

View full text Add to dashboard Cite

Objectives: Antioxidant defense status was investigated in HIV-infected patients by measuring serum selenium, erythrocyte glutathione peroxidase (GSH-Px) activity, plasma thiol (-SH) and glutathione (GSH) concentrations along with the assessment of the clinical stage and surrogate markers of HIV-disease. Design, setting and subjects: Serum selenium levels were determined cross-sectionally in 104 sequentially selected HIV-infected patients (83 outpatients and 21 patients with ongoing AIDS de®ning events). The patients were classi®ed into three stages of the disease, I, II and III according to the 1993 Centers For Disease Control (CDC) classi®cation system for HIV-infection. GSH-Px activities, plasma SH and plasma GSH concentrations were determined in a subset of 24 patients at stage I and 12 patients at stage III with an active AIDS-de®ning disease. Results: Mean serum selenium levels were lower in CDC stage II (68.7 AE 20.9 mg/l; P`0.01; n 34) and stage III (51.4 AE 14.7 mg/l; P`0.01; n 37) HIV-infected patients than in healthy subjects (89.2 AE 20.9 mg/l; n 72) and stage I patients (82.3 AE 20.5; mg/l; n 33). Serum selenium levels were positively correlated with CD4-count (r 0.42; P`0.001; n 104) and inversely with levels of soluble tumor necrosis factor receptors type II (r 7 0.58; P`0.01; n 35), neopterin (r 70.5; P`0.001; n 80) and b2-microglobulin (r 70.4; P`0.001; n 94). Hepatitis C virus (HCV) and HIV-coinfected patients at CDC stages I and II showed markedly lower selenium concentrations compared to HIV-infected patients without concomitant HCVinfection. Serum selenium and GSH-Px activity in hospitalized AIDS patients was signi®cantly lower as compared to asymptomatic patients and healthy subjects, whereas plasma SH and GSH concentrations were lower in both, asymptomatic -and AIDS-patients, than in the controls. Conclusion:The results show that stages I±III of HIV-disease are characterized by signi®cant impairments of antioxidative defenses provided by selenium, GSH-Px, SH-groups and GSH. Sponsorship:

show abstract

Section: Discussionsupporting

confidence: 93%

Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection

Look

Rockstroh

Rao³

et al. 1997

Eur J Clin Nutr

138

View full text Add to dashboard Cite

show abstract

“…In parallel with the diminished production of Th1 ILs in HIV disease, there is a reduction in selenium levels with disease progression [4,[19][20][21]. Selenium deficiency occurs more frequently in HIV-seropositive persons with disease progression as documented by low plasma and red blood cell selenium levels [4,19,21].…”

Section: Selenium Hiv Infection Il-2 and Hiv Replicationmentioning

confidence: 99%

“…Selenium's immunologic properties include the seleniumdependent glutathione peroxidase system that protects against oxidative stress and is increased in HIV disease [1,3,4,[19][20][21]. The selenium-glutathione peroxidase system uses reducing equivalents from glutathione to catabolize hydrogen peroxide and protect cells from the oxidant molecules that are increased as a result of chronic immune activation.…”

Section: Selenium Hiv Infection Il-2 and Hiv Replicationmentioning

confidence: 99%

Selenium and Interleukins in Persons Infected with Human Immunodeficiency Virus Type 1

et al. 2000

View full text Add to dashboard Cite

An important role for selenium in human immunodeficiency virus (HIV) disease has been proposed. Decreased selenium levels, as found in persons with HIV infection or AIDS, are sensitive markers of disease progression. Selenium deficiency, an independent predictor of mortality in both HIV-1-infected adults and children, is an essential micronutrient that is associated with an improvement of T cell function and reduced apoptosis in animal models. In addition, adequate selenium may enhance resistance to infections through modulation of interleukin (IL) production and subsequently the Th1/Th2 response. Selenium supplementation up-regulates IL-2 and increases activation, proliferation, differentiation, and programmed cell death of T helper cells. Moreover, selenium supplementation may down-regulate the abnormally high levels of IL-8 and tumor necrosis factor-alpha observed in HIV disease, which has been associated with neurologic damage, Kaposi's sarcoma, wasting syndrome, and increased viral replication. Together, these findings suggest a new mechanism through which selenium may affect HIV-1 disease progression.

show abstract

“…[27]. Similarly, taking 200 μgr daily Se supplements for 2 years considerably improved Se levels but had no effect on CD4+T cell count.…”

Section: Introductionmentioning

confidence: 99%

Protocol of Determining the Effect of Selenium Supplementation on CD4 + T Lymphocyte Count in HIV/AIDS Patients: A Randomized Double Blind Placebo Controlled Trial

Yousefi¹,

Hadadi²,

Ostovar³

et al. 2011

AID

View full text Add to dashboard Cite

show abstract

Serum selenium concentration and disease progress in patients with HIV infection

Cited by 90 publications

References 16 publications

Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection

Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection

Selenium and Interleukins in Persons Infected with Human Immunodeficiency Virus Type 1

Protocol of Determining the Effect of Selenium Supplementation on CD4 + T Lymphocyte Count in HIV/AIDS Patients: A Randomized Double Blind Placebo Controlled Trial

Contact Info

Product

Resources

About